Professional
Added to YB: 2024-08-07
Pitch date: 2024-06-30
NVO [bullish]
Novo Nordisk A/S
-65.49%
current return
Author Info
Long Equity runs a quality growth portfolio of companies with high returns on capital and high free cash flow per share growth. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 140.41
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Long Equity Portfolio Holding: Novo Nordisk A/S
NVO: Diabetes care leader, 63% sales N. America, 6% China. Revenue: GLP-1 71%, insulin 28%, obesity 24%. Strong brand, innovative R&D. Growth from emerging markets, obesity treatment advances. Competitive edge in global diabetes epidemic. Focus on GLP-1 receptor agonists & insulin.
Read full article (1 min)